A Post-Intervention Surveillance Study Regarding the Acquisition Rate of ESBL-KP, Ecoli

Completed

• Conditions: Infection

• Registration Number: NCT00724919
• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Brief Summary

To determine the acquisition rate of ESBL producing E. coli or K. pneumoniae, post- intervention in the selected medical centres

Detailed Description

This is post-interventional study to follow the acquisition rate of ESBP producing E. coli or K. pneumoniae at the sites involved in a previous interventional study.

Study Timeline

• Study Start: 2003-12
• Primary Completion: 2004-04
• Study Completion: 2004-04
• Study First Submitted: 2008-07-23
• Study First Submitted QC: 2008-07-25
• Study First Posted: 2008-07-30
• Status Verified: 2008-08
• Last Update Submitted: 2008-08-07
• Last Update Posted: 2008-08-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 256

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The acquisition rate of ESBL producing E. coli or K. pneumoniae at the end of surveillance phase	48hours

Secondary Outcome Measures

Name	Time	Method
The infection rate due to ESBL producing E. coli, or due to K. pneumoniae at the end of surveillance phase	48hours